cyrilzakka/clinical-trials huggingface dataset:
Automitochondrial Transplantation Improves Live Birth in Elderly Patients With Low Prognosis After Repeated IVF Failure

The goal to this clinical trial is to study the effectiveness and safety of automitochondrial transplantation of urine derived stem cells(USCs) in in elderly patients with low prognosis after repeated IVF failure. The main questions it aims to answer are:

(1）test the effectiveness and safety of automitochondrial transplantation of urine derived stem cells (2) establish intracytoplasmic sperm injection(ICSI) mitochondrial transplantation platform Participants will be asked to:1)urine collections to further culture of autologous USCs 2)ovarian stimulation、trigger eggs、ICSI with autologous mitochondria 3）embryo transfer 4)accept pregnancy follow-up at given point


Eligibility Criteria:
Inclusion Criteria:

1. 1) At least 35 years old
2. 2) Repeated IVF failure: more than or equal to 2 egg retrieval with poor embryo quality, no transplanted embryos or failed embryo transfer (more than or equal to 4 embryos)
3. 3) Egg number ≤9
4. 4) Participate voluntarily and sign informed consent.

Exclusion Criteria:

1: Infertility caused by severe oligospermia, severe intrauterine adhesions, genital tract malformations, thyroid dysfunction and other endocrine, immune system, tumor and genetic diseases
Surgical Practices in Algeria : the Cholecystectomy

An anonymous national survey involving all practicing Algerian surgeons was conducted. At the end of the survey, all data were captured and processed using the SPSS v20 software; χ 2 tests were used to compare different groups of surgeons.

An anonymous national survey involving all practicing Algerian surgeons was conducted, this survey started the 1st November 2016 and ended the 1st September 2017.

Any digestive , general and visceral surgeon practicing in Algeria was eligible for this survey, surgeons in training "residents" and Algerian surgeons exercising overseas was systematically excluded.

The aim was to analyse some practice in accordance with the recommendations of the Society of American Gastrointestinal and Endoscopic Surgeons who published a guideline in 2010.

This elaborated form was an electronic one; it was performed using the open electronic platform "Google Form", the conception of the form was made by A.Tidjane "surgeon" and he was the first participant to this survey, considering his participation he was excluded from the seizure of the data. The analysis and interpretation of data was made by S.Benilha "bio-statistician", B.Tabeti "surgeon" and A.Tidjane.

The form consisted of two parts, the first concerning the surgeon's Wilaya of exercise, the rank of health structure of practice, his professional position , and the year of his graduation , the second part concerning his practices during the performing CH and the questions concerned the use of laparoscopy or open surgery to perform CH, the number of Trocars used, the technique to access the peritoneal cavity, the surgical technique, the use of intraoperative cholangiography "IOC", the technique of extraction of the gallbladder, systematic gallbladder macroscopic and histological examination, the systematic abdominal cavity drainage, systematic use of postoperative antibiotic prophylaxis, and the optimal duration of postoperative stay in the case of optimal patient with no preoperative incident or postoperative complication. At the end of the survey a question was asked to surgeons about the occurrence during their professional practice of an operative bile duct injury.

The language of instruction of surgeons in Algeria is French; the French was used to draft this form. This electronic form was distributed by email to all surgeons in the authors Mail lists, those first contacted surgeons had the mission not only to participate in this survey but also had the mission of distributing the electronic form to their surgeon colleagues. All incomplete responses were excluded.

Statistical analyses:

At the end of the survey, all data were captured and processed using the SPSS v20 software (IBM Inc., Chicago, IL, USA), a χ 2 tests were used to compare some surgical practices in different groups of surgeons, a (P \< 0.05) was considered statistically significant.

Eligibility Criteria:
Inclusion Criteria:

* visceral an general surgeons practicing in Algeria.

Exclusion Criteria:

* surgeon under training.
* Algerian surgeon practicing abroad.
Single Incision Pelvic Floor Mesh Implants

Objectives: To evaluate whether the use of single incision un-anchored small mesh implants is feasible, safe and effective for women with moderate pelvic organ prolapse.

Design: Patients diagnosed with moderate pelvic organ prolapse were enrolled to undergo a single incision un-anchored mesh operation. Follow-up was 4 to 23 months. The outcome measures for this study were the operative safety and post-operative pain, adverse effects and anatomical as well as functional cure.

Setting: The operations were performed under general anesthesia according with the reported surgical techniques at university and private hospitals.

Eligibility criteria: female patients with moderate pelvic organ prolapse Outcome measures: intra operative safety and surgical complications, post operative complications and objective as well as subjective cure rates

Eligibility Criteria:
Inclusion Criteria:

\* Patients with Gr 2-3 Pelvic Organ Prolapse

Exclusion Criteria:

\*Previous Pelvic irradiation
Deep Dry Needling for the Management of Post-stroke Spasticity

Stroke is the leading cause of physical disability, particularly due to the presence of spasticity. Different needling techniques, including the use of Botulinum Toxin A are proposed for the management of spasticity. The presence of spasticity in the lower extremity implies several impairments for standing and walking inducing high disability. No study has investigated the effects of deep dry needling inserted into the targeted spastic musculature in patients with stroke. The investigators will conduct a randomized controlled trial investigating the effects of a single session of deep dry needling over the musculature of the leg on spasticity, widespread pressure pain sensitivity and plantar pressures (baropodometry) in individuals with chronic stroke. The investigators hypothesize that patients receiving a single session of dry needling would exhibit a greater reduction in spasticity and pressure sensitivity than those who will not receive the intervention.


Eligibility Criteria:
Inclusion Criteria:

* First-ever unilateral stroke;
* hemiplegia resulting from stroke;
* unilateral equinovarus gait with independent walk;
* able to ambulate without supporting devices.

Exclusion Criteria:

* recurrent stroke;
* previous treatment with nerve blocks, motor point injections with neurolytic agents for spasticity at any time, or with BTX-A in the previous 6 months
* not independent in the basic activities of daily living
* severe cognitive deficits;
* progressive or severe neurologic diseases;
* fear to needles;
* any contraindication for dry needling, e.g., anticoagulants, infections, bleeding, or psychotic.
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo.

The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.

The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.


Eligibility Criteria:
Inclusion Criteria:

* Have a diagnosis of primary ITP, defined as isolated thrombocytopenia not associated with another known disease process
* Have documented history of response, defined as 2 or more platelet counts greater than or equal to 50,000/microliter (μL), to at least 1 prior line of therapy. Splenectomy is considered a line of therapy
* Have relapsed or treatment-resistant primary ITP, with no available therapies known to provide clinical benefit
* Have a platelet count less than 30,000/μL on 2 occasions more than 5 days apart in the 15 days before randomization
* Have adequate liver, renal, and hematologic functions as defined by a table
* Are willing to follow contraception requirements

Exclusion Criteria:

* Have a history of any thrombotic or embolic event within 12 months before screening
* Had a transfusion with blood or blood products or plasmapheresis within 14 days (Phase 1) or within 28 days (Phase 2) of randomization
* Have significant cardiovascular disease
* Have a diagnosis or history of hematologic malignancy
* Have hepatitis B virus (HBV) defined as positive for antigen of hepatitis B (HBsAg) or polymerase chain reaction (PCR) positive for HBV deoxyribonucleic acid (DNA)
* Have hepatitis C virus (HCV) defined as positive for anti-HCV antibodies and PCR positive for HCV ribonucleic acid (RNA)
The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers

This study evaluates the role of narrow band imaging (NBI) endoscopy compared with Lugol chromoendoscopy in the early detection of esophageal cancer in patients with prior head and neck cancers.

Patients with head and neck cancers have an increased risk for developing an esophageal squamous cell carcinoma (ESCC). Small, superficial, curable lesions are difficult to diagnose using only white light endoscopy. To improve detection chromoendoscopy is recommended. In this project patients are divided into two groups based on received chromoendoscopy (NBI versus Lugol). The results of two methods will be compare regarding positive predictive value to establish usage of chromoendoscopy in early detection of ESCC.

Eligibility Criteria:
Inclusion Criteria:

* Patients with past history ( \>= 1 year ) of head and neck cancer treated curatively and receiving regular follow - up at the outpatient clinic of the Head and Neck Department of Maria Skłodowska - Curie Memorial Cancer Center, Institiut of Oncology
* 18 years and older
* Diagnosis of squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx
* Zubrod scale 0-2
* Provided written informed consent

Exclusion Criteria:

* Lack of written informed consent
* Known allergy to iodine
* Clinical conditions precluding upper GI endoscopy
Use of Shear Wave Elastography for Intraoperative Brain and Glioma Stiffness Measurements

This study investigates the role of intraoperative shear wave elastography ultrasound (ISWEU) in identifying healthy brain and tumor tissue stiffness differences. This data may be used to guide tumor resection in future patients.

PRIMARY OBJECTIVE:

I. Determine the feasibility of utilizing ISWEU measurements intraoperatively and in the human brain to measure tissue stiffness.

OUTLINE: This is an observational study.

Patients undergo shear wave elastography ultrasound over 10-15 minutes during their standard of care surgery on study.

Eligibility Criteria:
Inclusion Criteria:

* Patients must be at least 18 years old.
* Patients must have planned surgery for resection of a newly diagnosed or recurrent glioma.
* Patients with tumors located in the brain cortex or superficial white matter in which introduction of the ultrasound probe is straightforward and does not pose a risk for intraoperative complications.
* Patients must have a Karnofsky performance status ≥ 60%.
* Patient or legally authorized representative (LAR) willing to provide written informed consent.

Exclusion Criteria:

* Patients with deep-seated brain tumors in which introduction of the ultrasound probe poses an increased risk.
* Patients with a history of any brain infections.
* Patients with implanted devices.
* Patients with any other neurological/neurosurgical disease that could affect tissue stiffness.
* Patients with any other structural brain defect that could affect tissue stiffness.
Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Subject with CTEPH having completed the double-blind (DB) AC-055E201/ MERIT-1 study as scheduled (i.e., who remained in the DB study up to Week 24).
* Females of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception.

Exclusion Criteria:

* Permanent discontinuation of DB study treatment due to an hepatic adverse event or liver aminotransferase abnormalities.
* Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable psychiatric illness) that, in the opinion of the investigator, may interfere with treatment compliance or interpretation of the results, or that may influence the ability to comply with any of the study requirements.
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.

This is an open-label study for patients who participated in the BPS-MR-PAH-201 study and have volunteered to continue treatment for PAH with BPS-MR tablets. Each patient will return to the clinic following enrollment in the study at 3, 6, and 12 months, and annually thereafter for assessment.

Currently enrolled patients may be invited to participate in an optional four times daily (QID) dosing substudy of BPS-MR with total daily dose of BPS-MR achieved previously in the main study. Patients will return to the clinic for baseline visit, week 12, and then will follow the visit schedule provided to them in BPS-MR-PAH-202 main study.

Eligibility Criteria:
Inclusion Criteria:

* Patients who remained on study drug and completed all assessments during the Treatment Phase of Study BPS-MR-PAH-201 are eligible for this study.
* Female patients must either be physiologically incapable of childbearing or be practicing an acceptable method of birth control (e.g. approved hormonal contraceptive, barrier method, such as condom or diaphragm, used with a spermicide, or an intrauterine device).

Exclusion Criteria:

* Patients who discontinued study drug during the previous study (BPS-MR-PAH-201) for any reason (e.g. treatment related adverse events) are not eligible for entry into this study.
* Patients who are pregnant or lactating are excluded from participation in the open-label extension.
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.


Eligibility Criteria:
Inclusion Criteria

Subjects must meet the following criteria for entry into the study:

1. Male or female \> 65 years of age at the time of consent;
2. Understand and voluntarily sign an informed consent form;

Inclusion criteria is assessed at both e-consent (assessed by participant's self-reporting of age and understanding) and in-person consent at TRI (assessed by clinical research coordinators in TRI).

Exclusion Criteria

Subjects who meet any of the following criteria will not be eligible for entry into the study:

1. Subjects who are unable to hear and see well enough to complete the assessments;
2. Prior diagnosis of dementia or Alzheimer's disease documented in their medical record and/or as diagnosed by a physician; Exclusion criteria is assessed by by participant's self-reporting of understanding and not having a prior diagnosis of dementia at the time of e-consentand visit 1 at TRI. ).
A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion

A Randomized, Subject-Assessor Blind, Multi-center, Comparative Clinical Trial to evaluate the efficacy and safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion.


Eligibility Criteria:
Inclusion Criteria:

The subject needs the infusion between the first lumbar vertebrato and the first ilium from those who require posterior spinal instrumentation and interbody fusion for the following reasons,

* Spinal stenosis
* Spinal disc herniation requiring broad laminectomy
* Spondylolisthesis or spondylolysis
* Recurrent herniated disc

Exclusion Criteria:

* Patients with BMD T-score \< -3.0
* Women who are pregnant or plan to be pregnant within study period
Diaphragmatic Height Index: the New Diagnostic Test for Phrenic Nerve Dysfunction

Diaphragmatic contraction is controlled by phrenic nerve which consists of anterior rami of 3rd- 5th cervical nerve roots. Usually, It can't be evaluated from history taking and physical examination. Thus the diaphragmatic elevation on chest radiograph is assumed to identify the phrenic nerve dysfunction. Normally, the right diaphragm is higher than the left side about 1.5 ± 0.9 centimeters or 0.5 ± 0.3 time of vertebral height. Although there are several methods to determine the diaphragmatic elevation from previous studies, the accuracy, reliability, intra and inter-observer variation are problem.

Neurotization is the effective procedure to restore upper extremity function in root avulsion type. Phrenic nerve is one of the common donor nerves which used for this procedure. But sometimes, concomitant injury of this nerve can occur. Therefore, the investigators established "Diaphragmatic height index (DHI)" from chest radiograph to use as the diagnostic test for phrenic nerve dysfunction.


Eligibility Criteria:
Inclusion Criteria:

* Brachial plexus injured patients who underwent the neurotization in our institute between 2005-2008
* Non brachial plexus injured patients who underwent the other orthopedic operation in our institute between April-June 2009

Exclusion Criteria:

* Concomitant pneumothorax and/or hemothorax
* Concomitant pulmonary contusion
* Previous pulmonary disease
* Chest wall deformity
* Thoracic or thoracolumbar scoliosis (\>10 degrees)
* Hepatomegaly
* Incomplete data
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled.

This study is seeking participants who:

* have lung cancer that could not be controlled.
* have a type of gene called a ROS proto-oncogene 1. A gene is a part of your DNA that has instructions for making things your body needs to work.
* have received at least 1 treatment before.

All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take lorlatinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.


Eligibility Criteria:
Inclusion Criteria:

1. Patients are aged 18 years or older on index date
2. Patients have confirmed diagnosis of ROS1-positive NSCLC
3. Patients have received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023

Exclusion Criteria:

1. Patients participated in any clinical trials using lorlatinib during the observation period.
Love Together, Parent Together: A Protocol for a Pilot Study of an Intervention for Interparental Couples With Young Children

The COVID-19 pandemic has created a population-level threat to social relationships that requires a population-level solution. Among those who are particularly vulnerable to heightened conflict are interparental couples with young children, whose relationships may have already been under pressure prior to the pandemic. Reduced couples' satisfaction has been reported since the start of the pandemic, with over one-third of romantic partners reporting heightened conflict due to COVID-19. Couples are likely to stay in disharmonious relationships during times of socioeconomic upheaval, with the potential for relationship problems to persist over time. This may have serious implications for the mental health of parents, parent-child relationships, and children's emotional and behavioural problems (EBPs). Such a pattern is a societal concern given the known associations between couples' relationship quality and a number of critical indicators of population health, such as intimate partner violence, physical health and all-cause mortality, and economic instability, particularly for women. The current study protocol is for a pilot randomized controlled trial (RCT) of the Love Together Parent Together (L2P2) program-a brief, low-intensity, scalable relationship intervention for parents of young children. The two-arm (treatment vs. waitlist) pilot RCT will assess the feasibility goals: continued relationship-building with established recruitment partners and outreach to additional recruitment partners to increase enrolment rates; recruitment of a diverse sample in terms of sociocultural identity factors, pandemic-related stress, and relationship distress; acceptability of randomization; outcome assessment schedule completion (for treatment and control groups), retention and adherence to the program; and program acceptability. Additionally, the investigators will conduct a preliminary evaluation of treatment effects by examining group differences in couples-focused (i.e., couples' relationship, conflict-related negativity, interparental functioning) and family-focused outcomes (i.e., parent-child relations, parent mental health and child outcomes). A scalable couples-focused intervention is critically needed to circumvent the social consequences of the pandemic on young families.


Eligibility Criteria:
Inclusion Criteria:

* Both participants endorse being in a relationship
* Both partners reside in the same house
* There are one or more children under the age of 6 living at home
* Both participants are over age 18 years
* Both members of a couple agree to participate

Exclusion Criteria:

- No current plans or history of separation or divorce